Phillip P. Chan - Dec 29, 2021 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Role
Chief Executive Officer
Signature
/s/ Kathleen P. Bloch attorney-in-fact for Phillip P. Chan
Stock symbol
CTSO
Transactions as of
Dec 29, 2021
Transactions value $
$60,749
Form type
4
Date filed
1/3/2022, 07:00 PM
Previous filing
Dec 13, 2021
Next filing
Jun 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTSO Common Stock Purchase $404 +100 +0.01% $4.04 754K Dec 29, 2021 Direct F1
transaction CTSO Common Stock Purchase $38.2K +9.44K +1.25% $4.05 763K Dec 29, 2021 Direct F1
transaction CTSO Common Stock Purchase $22.1K +5.46K +0.72% $4.05 768K Dec 30, 2021 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were open market purchases made by the reporting person pursuant to a trading plan adopted on December 9, 2021 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
F2 Includes the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015.
F3 Includes the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of the Issuer's common stock upon vesting: (a) 48,000 RSUs granted on April 12, 2021 and unvested on the date hereof, and (b) 20,000 RSUs granted on February 28, 2020 and unvested on the date hereof, and
F4 Includes 484,443 shares of the Issuer's common stock owned by the reporting person, inclusive of the 15,000 shares of the Issuer's common stock reported on this Form 4.